#United States #Cambridge #MetaVia Inc #GLP-1 Agonist #DA-1726

MetaVia Begins Higher-Dose Phase 1 Study of DA-1726

In an exciting development for tackling obesity, MetaVia Inc., a biotechnology company listed on Nasdaq as MTVA, has announced that it has successfully dosed the first patient in Part 3 of its Phase 1 clinical trial for DA-1726. This innovative treatment is a dual agonist targeting both GLP-1 and glucagon receptors, designed to combat obesity and related cardiometabolic diseases. The study aims to explore higher dosage levels, evaluating the safety and effectiveness of DA-1726 in a structured manner.

Overview of the Trial

The Phase 1 trial, which spans two parts, plans to enroll a total of 40 healthy adult participants categorized as obese. In each arm of the study, participants will be randomized to receive either the investigational active drug or a placebo.

• - Part 3A will utilize a one-step titration regimen, administering 16 mg for 4 weeks, followed by an increase to 48 mg for the subsequent 12 weeks.
• - Part 3B will test a more incremental two-step titration, starting with 16 mg for 4 weeks, then increasing to 32 mg for another 4 weeks, before finally reaching 64 mg for the last 8 weeks of the trial.

Through this structured approach, MetaVia aims to not only ascertain the safety and tolerability of DA-1726 but also its pharmacokinetics and pharmacodynamics. Researchers will meticulously track adverse events, ensuring a comprehensive evaluation of participant safety throughout the duration of the study.

Promising Preliminary Outcomes

Initial data has already showcased the potential of DA-1726, noting an approximate 9% weight reduction at the 48 mg dose, alongside significant decreases in waist circumference and improved glycemic control. Moreover, early indicators suggest direct benefits to liver health, all while maintaining a favorable profile in terms of tolerability.

"Dosing the first patient in these higher-dose cohorts is an exciting milestone that moves us closer to unlocking the full potential of DA-1726," commented Hyung Heon Kim, President and CEO of MetaVia. This enthusiasm shines a light on their strategy to achieve higher therapeutic doses that could potentially surpass the efficacy of currently available weight loss solutions, which traditionally require more gradual titration times.

What Makes DA-1726 Special?

DA-1726 is classified as a novel oxyntomodulin (OXM) analogue. By acting as a dual agonist, it engages both GLP-1 and glucagon receptors, leading to weight loss through appetite suppression and an increased energy expenditure rate. This dual-action mechanism has already demonstrated superior weight-loss results in preclinical models when compared with other leading therapies such as semaglutide and tirzepatide. The therapeutic approach underpins the potential effectiveness for patients seeking enhanced metabolic health amidst rising obesity rates globally.

MetaVia’s commitment to transforming the landscape of cardiometabolic disease management makes the upcoming data, expected by the fourth quarter of 2026, a key point of interest. As researchers aim to share their findings, further encouragement surrounds DA-1726's capability to provide differentiated efficacy and a streamlined path for patient treatment.

Looking Ahead

As obesity remains a persistent global health issue, the continuing advancements within MetaVia are notable. By concentrating on innovative, effective therapies like DA-1726, the company stands at the forefront of battling this epidemic. For those looking for additional information on the ongoing trial, further details can be found on clinicaltrials.gov under the identifier NCT06252220.

About MetaVia

MetaVia Inc. dedicates itself to advancing treatment options for cardiometabolic diseases and is also developing vanoglipel (DA-1241) for the therapeutic management of Metabolic Dysfunction-Associated Steatohepatitis (MASH). As healthcare continues evolving, the firm’s efforts highlight the critical importance of innovative biotechnology solutions in addressing significant health challenges.